Specialty Pharmacy

Research seeks to determine how cancer cells avoid chemotherapy.

High level of benefit found in Gazyva compared with bendamustine.

Test projects which agent will work best against particular tumors.

Pharmacy-based transition of care (TOC) interventions that include post-discharge medication therapy management (MTM) services are strongly correlated with reduced hospital readmissions.

The FDA has granted priority review to Merck's pembrolizumab (Keytruda) for the treatment of advanced non-small cell lung cancer (NSCLC).

Melanoma incidence increased 250% in children, adolescents and young adults since 1973.

Gene mutations found in some patients provide hope for new and existing treatments.

Patients with a fast resting heart rate may have a higher risk of developing type 2 diabetes.

Predictive model uses routine lab values and machine learning method.

Amy Grogg, PharmD, senior vice president of Strategy and Commercialization at AmerisourceBergen Specialty Group discusses how the relationship between manufacturers, providers, and specialty pharmacies can be improved.

Merck is seeking FDA approval for its once-daily, single-tablet grazoprevir/elbasvir combination for the treatment of adult patients with chronic hepatitis C virus (HCV) genotypes 1, 4, or 6 infection.

A pair of large RNA classes associated with a protein that may play a role in cancer progression.

Top stories of the week on Specialty Pharmacy Times from May 25 to May 29.

Uncertainty persists in how collagen influences cancer cell behavior.

Nearly 1 in 4 patients treated in childhood for Hodgkin's lymphoma developed a second type of cancer within 30 years.

Legislation has been introduced in Congress to rein in skyrocketing generic drug prices.

Treatment advances have caused significant progress in survivorship.

Monitors alert health workers when a vaccine has potentially been compromised by cold chain failures.

Treatment utilizes immune cells grown from patient bone marrow to treat multiple myeloma.

Protein that helps cancer cells avoid death offers promising target.

The FDA today approved sirolimus, the first drug to treat lymphangioleiomyomatosis, a rare lung disease.

Novel drug target found in cells directly responsible for cartilage damage in affected joints.

Treatment is the first concentrated mealtime insulin analog to be approved by the FDA.

Marc O'Connor, Chief Operating Officer of Curant Health, discusses potential methods for keeping high cost drugs accessible.

Amgen has terminated its co-development and commercialization of brodalumab with AstraZeneca after observing suicidal ideation and behavior in clinical trial participants.

Genetic variant found to be associated with the likelihood of patient response to interferon-beta.

Smokers face high risk of disease recurrence after completing treatment.

Discovery may accelerate search for effective vaccine.